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The Threshold of Toxicological Concern (TTC) concept can be applied to organic
compounds with the known chemical structure to derive a threshold for exposure,
below which a toxic effect on human health by the compound is not expected. The
TTC concept distinguishes between carcinogens that may act as genotoxic and non-
genotoxic compounds. A positive prediction of a genotoxic mode of action, either by
structural alerts or experimental data, leads to the application of the threshold value
for genotoxic compounds. Non-genotoxic substances are assigned to the TTC value of
their respective Cramer class, even though it is recognized that they could test positive
in a rodent cancer bioassay. This study investigated the applicability of the Cramer
classes specifically to provide adequate protection for non-genotoxic carcinogens. For
this purpose, benchmark dose levels based on tumor incidence were compared with
no observed effect levels (NOELs) derived from non-, pre- or neoplastic lesions. One
key aspect was the categorization of compounds as non-genotoxic carcinogens. The
recently finished CEFIC LRI project B18 classified the carcinogens of the Carcinogenicity
Potency DataBase (CPDB) as either non-genotoxic or genotoxic compounds based
on experimental or in silico data. A detailed consistency check resulted in a dataset
of 137 non-genotoxic organic compounds. For these 137 compounds, NOEL values
were derived from high quality animal studies with oral exposure and chronic duration
using well-known repositories, such as RepDose, ToxRef, and COSMOS DB. Further, an
effective tumor dose (ETD10) was calculated and compared with the lower confidence
limit on benchmark dose levels (BMDL10) derived by model averaging. Comparative
analysis of NOEL/EDT10/BMDL10 values showed that potentially bioaccumulative
compounds in humans, as well as steroids, which both belong to the exclusion
categories, occur predominantly in the region of the fifth percentiles of the distributions.
Excluding these 25 compounds resulted in significantly higher but comparable fifth
percentile chronic NOEL and BMDL10 values, while the fifth percentile EDT10 value was
slightly higher but not statistically significant. The comparison of the obtained distributions
of NOELs with the existing Cramer classes and their derived TTC values supports
the application of Cramer class thresholds to all non-genotoxic compounds, such as
non-genotoxic carcinogens.
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INTRODUCTION
In 2004, Kroes et al. derived TTC values for potentially genotoxic
substances from Carcinogenicity Potency DataBase (CPDB)
(Cheeseman et al., 1999; Gold et al., 1999). In the resultant
decision, three potentially genotoxic compounds were defined as
DNA-reactive mutagens. DNA-reactive mutagens are genotoxic
substances that can modify DNA directly, either as the parent
chemical or in the form of a metabolite (Boobis et al., 2017).
They have the potential to directly cause DNA damage when
present at low levels, leading to mutations and, therefore,
potentially causing cancer. This type of mutagenic carcinogen is
usually detected in Organisation for Economic Cooperation and
Development (OECD), Guidelines for the Testing of Chemicals,
such as the bacterial reverse mutation (mutagenicity) assay.
Further data that contribute to the classification are mouse
lymphoma assay or in vivo micronucleus test. In case of missing
data, the evaluation can be supported by rule-based and statistical
quantitative structure–activity relationship (QSAR) models. The
current TTC value for compounds with a structural alert for DNA
reactivity or experimental data for genotoxicity is 0.025 µg/kg/d.
Since the TTC limit for DNA-reactive genotoxic substances is
far below all other TTC values, the identification of experimental
data or structural alerts for genotoxicity is one of the first decision
points of the current TTC decision tree (EFSAWHO, 2016; More
et al., 2019).
In the case of non-directly DNA-reactive genotoxic
substances, a mechanism of action is assumed where a threshold
for tumor formation can be established. The most sensitive
effect(s) after chronic exposure of non-DNA reactive compounds
might, however, either be non-neoplastic or neoplastic effects,
depending on their mode of action. Within the TTC concept,
these substances, like all other chronically applied toxins, are
evaluated using the Cramer classification tree and the application
of the respective TTC values. This approach is supported by
European Food Safety Authority (EFSA) opinions of 2012
and 2016 (EFSA, 2012; EFSA WHO, 2016). In 2012, EFSA
compared (EFSA, 2012) the TD50 values of genotoxic and
non-genotoxic carcinogens from the Carcinogenicity Potency
DataBase (CPDB) and confirmed the finding of Cheeseman
et al. (1999) that non-genotoxic compounds are less potent than
genotoxic compounds.
As outlined by Boobis et al. (2017), the TTC value for
genotoxic carcinogens is currently based on a linear extrapolation
to a virtual safe dose, using one in one million lifetime tumor risk
levels in exposed individuals as target risk. Boobis et al. (2017)
pointed out that the major difference between the derivation
of the TTC for genotoxic substances and those for the Cramer
classes is the level of protection [which equals dividing the point
of departure (POD) by 106] for values of genotoxic carcinogens
vs. 102 for the chronic PODs of the Cramer classes. Reducing the
safety factor of the TTC values for genotoxic substances by three
orders of magnitude (i.e., using a margin of 103) would result
in a TTC value of 2.5 µg/kg/d, which is in the same range as
the Cramer class 3 value of 1.5 µg/kg/d. Despite this estimation,
Boobis et al. (2017) proposed the derivation of TTC values
for genotoxic (DNA reactive) and non-genotoxic compounds
following analysis of freshly curated carcinogen datasets.
The current analysis focused on non-genotoxic carcinogens,
since none of the previous analyses provided proof that the
application of Cramer class thresholds is safe for them. TTC
values for non-genotoxic carcinogens are currently derived using
the existing thresholds for the different Cramer classes. To
achieve the goal of this analysis, different points of departure
for non-genotoxic carcinogens were compared to identify
the most sensitive, and thus, most appropriate values for
threshold derivation.
In the LRI B18 2 project, the in vivo dataset for TTC was
extended with data from high quality (sub)chronic in vivo studies
for substances determined to be non-genotoxic carcinogens in
a rodent bioassay. The most sensitive dose descriptors from
these (sub)chronic studies were compared with benchmark
doses derived from tumor incidences; thereafter, they were
compared with the NOEL values of the actual Cramer classes
in terms of distributions and possible TTC values. Finally, the
use of Cramer class thresholds for non-genotoxic carcinogens
is discussed.
MATERIALS AND METHODS
Derivation of a Dataset of Non-genotoxic
Carcinogens
The dataset comprised 137 carcinogens derived originally from
the CPDB database (Cheeseman et al., 1999). These compounds
are identified as non-genotoxic carcinogens based on a decision
tree (CEFIC LRI B18 project) and a consistency check taking
into account further peer-reviewed publications. Publications
with any kind of tumor being significantly increased over the
background because of chemical exposure were considered.
All kinds of rodent bioassays were considered; and in case
of conflicting results, decisions were based on a weight of
evidence approach considering further mechanistic information.
Literature on genotoxicity was searched for in PubChem1 and
Pubmed2 by substance name and the terms “genotoxicity,”
“carcinogenicity,” or “mutagenicity.” Furthermore, european
chemicals agency (ECHAChem), national toxicology progamm
(NTP), and international agency for research on cancer
(IARC) reports were considered. Substances with a mode of
action irrelevant to humans were excluded. Most prominent
examples of substances excluded were such substances inducing
forestomach tumors in rodents (Proctor et al., 2007) or thyroid
stimulating hormone (TSH)-induced thyroid tumors (Bartsch
et al., 2018). Additionally, we added information on IARC (2021)
classification for all substances if available.
The CPDB documents tumor incidences per observed
tumor type, organ, gender, and dose group compared with
study controls and, if available, historical controls. The tumor
incidences were used to calculate the BMDL10 and ETD10 values
and include studies on different species, such as dog, hamster,
and monkey. The CPDB comprises 513 studies for the 137
chemicals. However, the cancer bioassay study design is often
focused on tumor detection alone, so non-neoplastic effects are
insufficiently investigated. To enable an analysis of NOEL values,
1Pubchem (2021). https://pubchem.ncbi.nlm.nih.gov/.
2Pubmed (2021). https://pubmed.ncbi.nlm.nih.gov/.
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OECD guideline-conformant (sub)chronic toxicity studies were
collected from high quality databases [RepDose (https://repdose.
item.fraunhofer.de), ToxREF DB (Martin et al., 2009), Cosmos
(Yang et al., 2017)] or from peer-reviewed publications. The
purpose of this analysis was to extend the study reports of the
CPDB with observed non-neoplastic effects, in particular the
lowest observed effect levels (LOELs) per gender, organ, and
effect. This search aimed to integrate at least one chronic study
per chemical in the dataset, especially for chemicals for which
only cancer studies were available in the CPDB.
A study quality measure assessing the study reliability in terms
of guideline alignment (as recorded in RepDose) was assigned
to each study to distinguish guideline-compliant studies from
studies of lower quality. In this context, the studies of lower
quality included cancer studies that miss other than cancer-
related chronic endpoints, studies with major deviations from
guidelines, as well as studies with a special focus and, thus,
deviating from the scope of the examination.
The final dataset of 137 chemicals comprised 525 studies with
repeated exposure: 190 subchronic (83–99 days) and 259 chronic
toxicity studies, and 76 cancer studies (>350 days). Rats or mice
were mainly tested orally, or, in a very few cases, by inhalation
(N < 5). In the case of inhalation, the route was selected
because of the volatility of the substances and 100% absorption
of the nominal concentration was assumed. The concentrations
administered in the inhalation studies were included as body dose
converted to mg/kg bw/d.
The Points of Departure
No Observed Effect Level Values
The respective NOEL values were calculated by the use of
an extrapolation factor of 3 for LOEL to NOEL, to minimize
the impact of differences in study design like dose spacing
(EFSA, 2012). The NOEL values were collected without further
consideration of adversity of effects from the RepDose database.
• The LOEL values were derived from (sub)chronic studies,
considering three different types of significantly increased
effects in the study:
• the lowest observed effect level of the overall study (LOEL)
• the lowest observed effect level of the most sensitive tumor
(neoplastic LOEL) and
• the lowest observed effect level of the most sensitive non-
neoplastic effect, defined as effect not diagnosed as a tumor
(non-neoplastic LOEL)
Allometric scaling was applied to account for interspecies
differences with a factor of 4 for rats and 7 for mice (EFSA,
2012). An extrapolation factor of 2 was applied for subchronic
to chronic extrapolation (ECHA, 2012) to compare the outcome
of different study durations. Out of these standardized NOEL
values, the lowest value per substance is considered. The
preferred unit of the standardizedNOEL values is mmol/kg bw/d;
and for final comparison with published datasets, values are, in
addition, given in mg/kg bw/d.
The first analysis of NOELs assessed the influences of study
quality and study duration on the respective fifth percentile of the
distribution of the NOELs. In the next step, we compared the fifth
percentile for the overall NOELs, and those for non-neoplastic
lesions and neoplastic tumors. The NOEL distributions deriving
the lowest fifth percentile were used for the following steps.
The resulting NOEL values per compound are provided in
Supplementary Table 1.
Effective Tumor Dose 10 Values
The effective tumorigenic dose for 10% of the animals for the
most sensitive tumor was determined by the previous project
LRI B18 (publication in preparation) on the same chemicals
but a different study repository was used. The inclusion criteria
for studies and their respective tumors were oral route, two
or more dose levels in addition to the control group, specific
tumor site, and quality-controlled evidence for human relevant
carcinogenicity. A significant relationship between dose and
tumor counts was analyzed based on contingency tables. The
doses of these tumors were fitted using logistic regression to the
proportion of tumor-bearing animals with a logit link function.
The Akaike information criterion (AIC) was used to characterize
the goodness of fit of the logistic regression model to dose-
response of the data set (AICnull). Studies with values of
AICnull—AIClogistic > 2 were used for further analyses. To
allow comparison with other PODs, allometric scaling factors
were applied to the ETD10 values, which were 4 (rat); 7 (mouse),
1.4 (dog), 5 (hamster), and 2 (monkey) (EFSA, 2012).
The resulting ETD10 values per compound are provided in
Supplementary Table 2.
Benchmark Dose Level 10 Values
The same study inclusion criteria outlined above for the
modeling of ETD10 were applied to calculate BMDL10. A
benchmark response (BMR) of 10% was predefined as the critical
effect size. BMDL10 values were standardized for allometric
differences as described above.
Model averaging was used to estimate the dose (BMDL10)
associated with the specified effect [within the PROAST software
(version 64.10; (Slob, 2002)]. The average BMD10 was estimated
from the complete dose–response dataset by fitting to the
available nine different dose–response models, which are named
according to their fitting functions as two.stage, log.logist,
weibull, log.prob, gamma, probit, logistic, expon, and hill.
Statistical uncertainties in the data are taken into account in
the 90th confidence interval around the BMD, the lower limit
of which (denoted as BMDL10) is the POD for risk assessment
(Hardy et al., 2017). For further reference, please refer to https://
www.rivm.nl/en/proast.
The resulting BMDL values per compound are provided in
Supplementary Table 2.
Robustness of Threshold of Toxicological
Concern Values
Derivation of Threshold of Toxicological Concern
Values
Before calculating the TTC value based on the fifth percentile of
the POD distributions, we investigated by manual inspection of
all chemicals up to the 30th percentile whether specific chemical
classes are associated with low NOEL values and, therefore,
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influence the fifth percentile. We analyzed the impact of these
chemical classes on the fifth percentile in comparison to leaving
out the same number of randomly selected chemicals. A KNIME
workflow was built to calculate the fifth percentile [type 8
(Hyndman and Fan, 1996)] leaving out a randomly predefined
percentage of substances with 100 repetitions. A random leave
out with 5/10/20 iterations excludes randomly 20/10/5% of the
substances from the whole dataset and calculates the respective
fifth percentile of the remaining 80/90/95% of the compounds.
After 5/10/20 iterations, each compound was excluded once. The
lowest and highest fifth percentiles calculated within the 100
iterations are recorded as possible range after random leave out.
In the case that the fifth percentile, after exclusion of a specific
group of chemicals, exceeds the range of TTC values that a
random set is left out, there is high probability that this substance
group has a specific impact on the remaining data set.
In order to derive TTC values, we assigned all the 137
substances to their respective Cramer classes using QSAR
Toolbox 4.3 and Toxtree v3.1.0.1851. There are deviations
between the two implementations and the original and extended
Cramer rules for 27 substances (19% overall, explicit data not
shown). The ranges of discrepancies are similar to those observed
by Bhatia et al. (2015). As discrepancies of this proportion are
not acceptable, we compared the concordance of the originally
published classification by Munro according to Cramer with
the classifications assigned by Toxtree and QSAR Toolbox:
Toxtree resulted in 66/607 (11%) original Munro DB chemicals
with deviating classifications compared with those assigned
originally, whereas QSAR Toolbox classifications deviated in
40/607 (7%) chemicals only. With both tools, the so-called
“original Cramer classification” was used. Based on these results,
the original Cramer classification by the QSAR Toolbox was used
in this project.
In the final step to derive a TTC value, we extrapolated the fifth
percentile to human exposure thresholds. As species differences
were accounted for by allometric scaling prior to the derivation
of fifth percentiles, the remaining extrapolation accounted for the
remaining uncertainty with respect to interspecies differences (a
factor of 2.5) and the intraspecies variability (factor of 10) (Escher
et al., 2010). This approach differs from that proposed by Munro
et al. (1996). They applied a default safety factor of 100 to the fifth
percentiles based on a margin of safety concept. NOEL values
from studies with less than chronic exposure were additionally
adjusted by a factor of 3. The consideration of the time difference
in NOEL values was not necessary in the current analysis, which
is based on chronic studies only.
Comparison of Distributions of Different Points of
Departure
The distributions of the log-normal values for NOELs, BMDLs,
and ETD10s were plotted in parallel histograms. This qualitative
comparison of the distributions is accomplished by derivation of
the respective TTC values and their confidence interval.
Statistical Analyses and Special Diagrams
Statistical analyses were performed using R [version 3.5.1 (2018-
07-02)]. The fifth percentiles are calculated using the quantile
type 8 function (Hyndman and Fan, 1996). Additional libraries
ggplot2 and ggridges were used for the respective plots. KNIME
was used for the leave-out workflow only.
RESULTS
Dataset and No Observed Effect Level
Values
The TTC dataset comprised 137 non-genotoxic compounds. All
the 137 compounds had at least one chronic toxicity study.
The majority (98 substances, 72%) has, at minimum, one high
quality chronic study, whereas 39 substances are described by
lower quality chronic toxicity studies alone. In addition, cancer
studies are available. The cancer studies were rated as being
of lower quality for the derivation of NOEL values, as they
are designed to detect carcinogenic effects and, thus, most
often apply relatively high doses without reporting on the non-
neoplastic effects, sometimes even focusing their results on the
major tumor-target organs.
Influence of Study Quality and Duration on the NOEL
To assess the impact of study quality and study duration on the
fifth percentile, data sets containing the same chemicals were
compared. This approach eliminates the potential influence of
different chemical domains. Fifth percentiles are similar for high
(5 × 10−5) and lower (1 × 10−5) quality studies as indicated by
the overlapping confidence intervals (CI 95%). Also, the study
duration has no significant impact on the fifth percentiles as
subchronic (4 × 10−5) and chronic (1 × 10−5) fifth percentiles
showed widely overlapping CIs (data not shown).
Neoplastic and Non-neoplastic Effects Determine the
NOEL
A slight shift to higher values is observed for the neoplastic
NOELs compared with non-neoplastic and overall NOEL values
(Figure 1). This finding raises the question of whether the data
support the widely spread thesis that in rodent bioassay tumors
occur at higher doses, or even only at the highest tested dose
(HTD) (Anisimov et al., 2005; van der Laan et al., 2016). In
the dataset, tumors occurred in 55% of the compounds at the
LOEL of the study. Tumor effects in isolation determined the
LOEL in 11% of all substances (whereas 44% showed both
non-neoplastic and neoplastic effects at the LOEL). Thirty-three
percent of the substances showed tumors only at the HTD but
other effects at lower doses. NOELs for the overall study as well
as non-neoplastic NOELs show the fifth percentile of 4 × 10−6
mmol/kg/d, whereas the fifth percentile of neoplastic NOELs
is slightly higher with 3 × 10−5 mmol/kg/d. The 95% CIs are
identical for the non-neoplastic NOELs and the NOELs. For
neoplastic NOELs, the 95% CI still overlaps with those of the
other two but is one order of magnitude broader, reaching to
higher values (see Figure 1, data for 95% CIs are not shown).
This analysis supports the observation of a broad overlap of
all NOEL distributions but about half of the substances included
in the analysis have neoplastic NOELs that are higher than the
overall NOEL. The overall NOELs of the chronic studies are, thus,
a conservative estimate for a POD.
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FIGURE 1 | Density plot with histograms for NOELs derived for different
endpoints with fifth percentile of each distribution represented by a dotted line
of the respective color.
Robustness of Threshold of Toxicological
Concern Values
Derivation of a Threshold of Toxicological Concern
Value
As the dataset serves to test whether or not the current TTC
concept is applicable to non-genotoxic carcinogens, it should
not include compound classes that are a priori excluded from
the applicability domain of the TTC concept (Kroes et al.,
2004; EFSA WHO, 2016). Within the dataset of 137 substances,
20 compounds show bioaccumulating properties in humans
(identified by experimentally measured half lives in vivo as
described by Corie Ellison et al. in preparation), and five
compounds are steroids (identification by steroid-like structure
and activity). These two classes are outside of the applicability
of the TTC concept, and, additionally, the steroids belong to the
cohort of concern. Bioaccumulating substances may, however,
exhibit excess toxicity because of their long-term stability and
result in high cumulative doses in humans, whereas steroids
are suspected to show adverse effects at very low doses. The
influence of these compounds on the fifth percentile was analyzed
by excluding them and comparing the resulting fifth percentiles
to randomly removing the same number of substances. Exclusion
of the bioaccumulative substances increased the fifth percentile
by a factor of 10, from 5 × 10−6 to 5 × 10−5 mmol/kg/d.
This increase is higher than when randomly removing a similar
number of compounds (20%), which results in a range of 2 ×
10−6 to 2 × 10−5 mmol/kg/d (Table 1). Subsequent exclusion of
five steroids resulted in the fifth percentile of 3 × 10−4 mmol/kg
bw/d, which is again higher than the range of 2 × 10−6 to
2 × 10−5 mmol/kg bw/d achieved by randomly removing the
same number of compounds. The cumulative frequency diagram
of NOELs shows that bioaccumulators and steroids are mainly
found at the lower end (Figure 2).
This analysis suggests that potentially bioaccumulating
compounds and steroids are predominantly found at the lower
end of the NOEL distribution, pushing the dataset toward lower
fifth percentiles. These classes should be excluded from the
datasets in order to derive relevant thresholds for compounds in
the applicability domain of the approach.
A similar analysis was carried out with the BMDL values
obtained by model averaging (Table 2, BMDL10). The analysis
discriminates BMDL10 values derived from studies with two or
more dose groups in addition to control (ID 1) from those based
on studies with three or more dose groups in addition to control
(ID 2). The results are in agreement with the results obtained for
NOELs (Table 1).
Comparison of the Fifth Percentiles for No Observed
Effect Level, Effective Tumor Dose 10, and
Benchmark Dose Level 10 Values
A comparative analysis of overall NOELs, ETD10, and BMDL10
values was performed to identify the most sensitive dose
descriptors for non-genotoxic compounds (Figure 3, Table 3).
ETD10 values were available for 118 substances and led to the
fifth percentile of 6 × 10−2 mg/kg/d. BMDL10 values for tumor
types being tested in studies with two or more dose levels were
calculated for 116 compounds. A BMDL10 value based on studies
with three or more dose levels was available for 62 substances.
Taking into account that benchmark dose modeling is dependent
on a dose–response curve, the dataset based on studies with three
or more dose groups (plus controls) is generally considered more
reliable than studies testing two dose groups. Nevertheless, both
BMDL10 datasets derived similar fifth percentiles, with 4× 10−2
and 3 × 10−2 mg/kg/d after exclusion of bioaccumulators and
steroids (Table 2).
These datasets for ETD10 and BMDL10 do not contain exactly
the same compounds, and this difference might interfere with a
direct comparison of PODs. Therefore, we compiled a dataset of
101 chemicals for which all three types of POD were available
(Figure 2, Table 3). The comparative analysis shows that for the
same substances, the fifth percentile is most conservative using
the overall NOEL values or the BMDL10. The fifth percentile in
the EDT10 dataset is slightly but not significantly higher.
The NOEL values are the largest dataset comprising all the
137 non-genotoxic compounds. Since the comparison of PODs
revealed NOELs to be a conservative estimate, the fifth percentile
NOEL value is used in the following to derive TTC values.
Cramer Classifications and Threshold of
Toxicological Concern Values
Most of the non-genotoxic carcinogens belong to Cramer class
3. Out of the 137 substances, 114 belong to Cramer class 3, 5 to
Cramer class 2, and 18 to Cramer class 1. The exclusion of the
potentially bioaccumulating substances and the steroids mostly
affects Cramer class 3, which is reduced to 90 compounds. These
90 compounds show the fifth percentile of 5 × 10−2 mg/kg/d
(Table 4). The distribution of the values is similar to the original
Munro data for Cramer classes 3 and 1 as shown in Figure 4.
For Cramer class 3, the number of substances in the non-
genotoxic dataset is sufficient to derive a TTC value, which turns
out to be similar to the original Cramer class 3: 2 µg/kg/d for
non-genotoxic compounds (range of 2–6µg/kg/d) and 1µg/kg/d
(range of 2–7 µg/kg/d) for the original Munro data. The ranges
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TABLE 1 | Impact of two different compound classes on the fifth percentiles in the NOEL dataset; ID 1- all NOEL values (N = 137 cmpds); exclusion of bioaccumulating
compounds (ID 2; N = 117; reduction by 20%) and subsequently steroid-like compounds (N = 112; additional reduction by 5%).






1 NOEL 137 5 × 10−6 n.a. n.a.
2 -bioacc. 117 5 × 10−5 20 2 × 10−6−2 × 10−5
3 -bioacc,
-steroids
112 3 × 10−4 5 4 × 10−5-2 × 10−4
The fifth percentiles after exclusion of bioaccumulating and steroid compounds are above those from removing a comparable number of randomly selected compounds, which indicates
that these substance classes have very low NOELs and are highly toxic.
FIGURE 2 | Cumulative frequency plot of NOEL values indicating subgroups of compounds, such as bioaccumulating in humans (bioacc) and steroids.
TABLE 2 | Overview on the fifth percentiles obtained from the BMDL10 datasets: ID 1 BMDL10 (N = 116 cmpds); ID1.1 -bioacc, -steroids (N = 100; reduction by ∼15%);
ID2 BMDL10 based on studies with at least three dose groups tested (N = 62); ID2.1 -bioacc, -steroids (N = 51; reduction by ∼20%).
ID Dataset N 5th percentile (mg/kg/d) 5th percentile after random removal
1 BMDL10 116 6 × 10
−3 5 × 10−3 – 2 × 10−2 (15%)
1.1 -bioacc, -steroids 100 4 × 10−2 n.a.
2 BMDL*10 62 4 × 10
−3 4 × 10−3 – 3 × 10−2 (20%)
2.1 -bioacc, -steroids* 51 3 × 10−2 n.a.
The fifth percentiles after exclusion of bioaccumulating and steroid compounds exceed those after removing a comparable amount of randomly selected compounds (15 and 20%,
respectively), which indicates that these substance classes have very low NOELs and are highly toxic. The fifth percentiles of ID1.1 and 2.1 show comparable results.
*Studies with more than three dose groups tested.
here are a measure of robustness toward random removal of 5%
of the substances (Table 5).
DISCUSSION
Like all other substances remaining after exclusion of
genotoxicants and those generally excluded from TTC,
non-genotoxic compounds are currently assigned to the Cramer
classes. This approach is based on the observation that tumor
formation is one of several chronic adverse effects and that the
underlying mechanisms show a threshold (Clewell et al., 2019).
This approach points to the question of whether non-genotoxic
carcinogens, in the context of TTC, are best described by their
most sensitive tumor or by their non-neoplastic adverse effects
and which dose descriptor is the most conservative.
The dataset used in this study was subject to a consistency
check, which included the exclusion of non-carcinogenic
compounds (Cefic, 2018) and non-human relevant tumor types
as well as an allocation of the mode of action (non-genotoxic
vs. genotoxic) by extensive literature review on available
experimental and predicted data.
Different points of departure were compared based on either
tumor incidences (EDT10, BMDL10) or the NOELs. The TD50
values used in the original CPDB database are not considered
to be conservative measures as they are based on a 50% tumor
rate. Furthermore, linear extrapolation to a virtual safe dose with
a tumor risk of 1–1,000,000 implicates high uncertainty. Thus,
the ETD10 values replace the TD50 values in this analysis.
This approach showed that the fifth percentiles derived from
the BMDL10, EDT10, and NOEL value distributions across > 100
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FIGURE 3 | Density plot with histograms for different types of PODs with
indication of the respective fifth percentiles by dotted lines in respective colors.
TABLE 3 | Fifth percentiles for NOEL, ETD10, and BMDL10 values.





NOEL 137 1.9 × 10−3 5 × 10−6
ETD10 118 6.0 × 10−2 1 × 10−4.
BMDL10 116 6.5 × 10−3 3 × 10−5.
Same Chemicals
NOEL 101 5.6 × 10−3 9 × 10−6
ETD10 101 7.1 × 10−2 2 × 10−4
BMDL10 101 7.3 × 10−3 3 × 10−5
carcinogens do not differ significantly indicating that for this
set of compounds tumor formation does not, per se, occur at
lower doses than those for non-neoplastic lesions. This is in line
with findings from a previous study, which showed that BMD
confidence intervals for tumor responses correlate with NOEL
values from (sub)chronic toxicity studies (Braakhuis et al., 2018).
Any of the three PODs could, thus, have been used to calculate
the TTC value for non-genotoxic compounds. In actuality, the
NOELs were used, since these values were available for more
compounds than the BMDL10 and EDT10 values.
The comparison of NOEL values for tumors and non-
neoplastic effects, as depicted in Figure 1, supports the
conclusion of the NOEL as the most conservative value. For
most of the substances (89%), LOELs are determined from non-
neoplastic effects, with half of the substances showing tumors
at this dose level. These LOELs are below the HTD (maximal
tolerated dose) for 67% of all the chemicals in this dataset. Since
several authors (Gaylor, 2005; Goodman, 2018) have argued that
the classical two-year bioassay by NTP will result in tumors at
the HTD, it is interesting to note that within this dataset tumors
do not primarily start to occur at the highest dose tested. The
observation of predominant non-neoplastic lesions supports the
hypothesis for the mode of actions of non-genotoxic compounds
made by Braakhuis et al. (2018). They stated that exposure
to low doses of non-genotoxic carcinogens will change some
biological processes slightly, whereas the repeated exposure will
lead to overt disturbances, e.g., in hormonal balance or redox
equivalents, inducing neoplastic changes, such as increased cell
proliferation (Braakhuis et al., 2018).
NOEL values of subchronic studies were additionally
compared with those of chronic studies to compensate for
possible deficiencies in the long-term study. Within this
comparison, the differences between the NOELs were not
higher than the well-established extrapolation factor of 2 for
subchronic to chronic exposure (EFSA, 2012). The data support
the hypothesis that there is no significant added value of
chronic studies neither with respect to POD (Braakhuis et al.,
2018) nor concerning the predictability of the effect (van der
Laan et al., 2016; Woutersen et al., 2016) for non-genotoxic
carcinogens. Nevertheless, we used the chronic dataset for
threshold derivation simply, as it was larger than that for
subchronic effects and covers a greater number of compounds.
It has been hypothesized that there may be a minimal (e.g., 5–
10%) response at the NOEL as opposed to the complete absence
of an effect. This discrepancy of the effect is most likely due to
the limited statistical power of the animal studies (Hardy et al.,
2017; Braakhuis et al., 2018). As shown in Figure 3, the data set
has no notable differences between the NOEL and the BMDL10,
supporting this hypothesis. Both values will feed into the final
analysis to derive TTC values.
Derivation and Assessment of Threshold of
Toxicological Concern Values for Cramer
Classes
The assignment of Cramer classes to the dataset is a prerequisite
for the derivation of the respective TTC values for Cramer
classes 3 and 1. The shortcomings and ongoing improvements of
Cramer classifications using the OECD Toolbox or Toxtree have
already been well-documented in previous publications (Bhatia
et al., 2015; Roberts et al., 2015; Boobis et al., 2017; Yang et al.,
2017). As we aimed to compare the TTC values to the original
values derived by Munro, we decided to use the original Cramer
decision tree from the OECD Toolbox for the classification of the
data set.
Most of the compounds in the dataset were assigned to
Cramer class 3. As commonly occurs, very few or no compounds
were assigned to Cramer class 3. As commonly occurs, very
few or no compounds were assigned to Cramer class 2 and
for this dataset only 18 compounds into Cramer class 1 (Patel
et al., 2020). The determination of a TTC value for Cramer class
1 compounds was, thus, not reasonable, as the fifth percentile
would be based on a single substance only. The NOEL values
of the 18 non-genotoxic carcinogens are consistently distributed
within the Cramer class 1 dataset (Figure 4). This preliminary
analysis is an indication that the Cramer class 1 threshold
can be applied to non-genotoxic compounds. The TTC of
Cramer class 3 on non-genotoxic carcinogens is 2 µg/kg/d
after exclusion of the possibly bioaccumulating substances and
steroids. The original Munro data derive a very similar TTC
value of 1 µg/kg/d. Other datasets, such as the COSMOS DB,
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TABLE 4 | Fifth percentiles of non-genotoxic datasets and original datasets by Munro for Cramer class 3 with respective ranges after randomly removing 5%.
Dataset mg/kg bw/d mmol/kg bw/d
NOEL N 5th P Range 5th P Range
-bioacc, -steroids 112 6 × 10−2 5 × 10−2- 2 × 10−1 3 × 10−4 4 × 10−5 – 2 × 10−4
Class 3 90 5 × 10−2 5 × 10−2- 1.5 × 10−1 2.5 × 10−4 2 × 10−4 – 4 × 10−4
FIGURE 4 | Cumulative frequencies of the original Munro data and non-genotoxic dataset for Cramer classes 1 and 3.
TABLE 5 | TTC values of non-genotoxic datasets and original datasets by Munro for Cramer Class 3 with respective ranges after randomly removing 5%.
TTC values N TTC* (µg/kg/d) Range TTC* (µmol/kg/d) Range
Class 3 90 2 2, 6 1 × 10−2 9 × 10−3 – 2 × 10−1
Munro Class 3 448 1 1, 1.3 2 × 10−2 9 × 10−3 – 2 × 10−2
*Calculated fifth percentile/25 as allometric scaling was applied to the NOEL before comparison.
for cosmetics show a TTC for Cramer class 3 of 7.9 µg/kg/d
(Yang et al., 2017), whereas the inhalation TTC value for toxic
substances is somewhat lower with 2 µg/person/d (Tluczkiewicz
et al., 2016). EFSA calculated a value of 1.5 µg/kg/d for the
original Munro dataset assigned to Cramer class 3 (EFSA
WHO, 2016). This comparison supports the safe application
of the Cramer class 3 TTC value to compounds being non-
genotoxic carcinogens.
A further extension of Cramer class 3 using data from
non-genotoxic carcinogenic herbicides, insecticides, fungicides,
and other agrochemicals is available with Heusinkveld et al.
(2020). For this list of chemicals, the RepDose DB contains
chronic LOEL and/or NOEL values from chronic studies for
95 chemicals. Following the same approach as before, these
95 compounds were assigned to Cramer classes (all were class
3), potentially bioaccumulating compounds were excluded, and
the respective fifth NOEL percentile was derived. Steroids were
not contained in this dataset. The fifth percentiles obtained are
16 µg/kg /d or 5 × 10−5 mmol/kg bw/d. These values are
similar to the percentiles derived for the non-genotoxic dataset
of this project and, thus, further, substantiate the applicability
of Cramer class 3 and the associated TTC value for non-
genotoxic carcinogens.
Robustness of the Threshold of
Toxicological Concern Values
The exclusion of substances exhibiting non-human relevant
mechanisms, as we did in the data set, is generally accepted
(Boobis et al., 2017), although it has been questioned before
(EFSAWHO, 2016).
The exclusion of several structural groups from the
application of the TTC is generally agreed (Boobis et al.,
2017), although reasons for exclusion differ: some structural
groups cannot be assessed by the TTC concept because they fall
out of the applicability domain. This means that compounds
with similar structural properties are not contained in the
TTC datasets, e.g., metals, proteins, inorganic salts, polymers,
etc. Other compounds, such as dibenzodioxin or-diphenyl-
derivatives, are known for their excess toxicity and potential to
bioaccumulate. For these compound classes, category-specific
TTC values, such as that for organophosphates, do not exist at
this time, as the value is likely to be too low to be practically
applicable. Nevertheless, some substances from these excluded
classes are part of the original Munro dataset, and their NOELs
contribute to the respective TTC values. This is due to the fact
that only few substances are concerned, and these are scattered
over the full range of NOELs.
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In the analysis, the exclusion of the potentially
bioaccumulating substances from the non-genotoxic data
has a significant influence on the TTC value derived from the
NOEL values. When the potentially bioaccumulating substances
were excluded, the resulting fifth percentile of the residual
chemicals is higher than the highest fifth percentile obtained
after 100 iterations of removing 20% of the whole dataset
randomly. Furthermore, the high toxicity of these substances has
already been widely accepted, as this is the reason for excluding
this group from TTC application. It is, however, discussed that
bioaccumulating substances are within the scope of the TTC
concept (Leeman et al., 2016). The definition of bioaccumulating
potential, as well as the dataset, was different in this publication,
especially the latter being the most probable reason for the
different outcomes. Through the application of the method of
random leave out, we nicely show in an objective way that the
excluded substances are distinct, and the very same reasoning
holds true for the steroids.
The method of randomly leaving out a certain number
of chemicals not only supports the exclusion of substance
groups but also indicates the robustness of the fifth percentile.
The smaller the dataset and the wider spread the NOEL
values, the higher the range after multiple random trials of
leaving out 5% of the substances. The similar ranges of about
a factor of 2–3 for all ranges of the TTC values increase
the confidence of the authors in the TTC values, as this
order of magnitude is approximately similar to one dose
spacing difference.
CONCLUSION
Existing in silico or in vitro methods to detect non-genotoxic
carcinogen mode of actions are insufficiently accurate yet
(Benigni et al., 2013; Papamokos and Silins, 2016). Consequently,
when applying the current TTC concept, structures cannot
reliably be identified as non-genotoxic carcinogens. Nevertheless,
it is commonly agreed upon that a threshold for non-genotoxic
compounds can be defined (Kroes et al., 2004). An important
question regarding the TTC concept is whether or not the
TTC values currently in use also apply to such compounds.
The datasets that have been used so far to derive the TTC
values contained non-genotoxic carcinogens as well as other
substances with chronic toxicity. With the current dataset of
non-genotoxic substances alone, supplemented by the dataset
used for replication, we were able to show that the application
of Cramer class 3 to unidentified non-genotoxic carcinogens is
appropriate. Also, the distribution of Cramer class 1 values for
non-genotoxic carcinogens falls within the distribution width of
the original Munro Cramer class 1 data. Within this process, we
confirmed that substances belonging to the cohort of concern
should be excluded from the datasets used to derive TTC
values, as they heavily influence the fifth percentile by their
high toxicity. The robustness of the TTC values in this study
was supported by a random leave out analysis of 5% of the
dataset compounds.
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